A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial | Zendy

Thomas J. Povsic | Zendy; John P. Vavalle | Zendy; Laura H. Aberle | Zendy; Jarosław D. Kasprzak | Zendy; Mauricio G. Cohen | Zendy; Roxana Mehran | Zendy; Christoph Bode | Zendy; Christopher E. Buller | Zendy; Gilles Montalescot | Zendy; Jan H. Cornel | Zendy; Andrzej Rynkiewicz | Zendy; Michael Ring | Zendy; Uwe Zeymer | Zendy; Madhu K. Natarajan | Zendy; Nicolas Delarche | Zendy; Steven L. Zelenkofske | Zendy; Richard C. Becker | Zendy; John H. Alexander | Zendy

Open Access

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial

Author(s) -

Thomas J. Povsic,

John P. Vavalle,

Laura H. Aberle,

Jarosław D. Kasprzak,

Mauricio G. Cohen,

Roxana Mehran,

Christoph Bode,

Christopher E. Buller,

Gilles Montalescot,

Jan H. Cornel,

Andrzej Rynkiewicz,

Michael Ring,

Uwe Zeymer,

Madhu K. Natarajan,

Nicolas Delarche,

Steven L. Zelenkofske,

Richard C. Becker,

John H. Alexander

Publication year - 2012

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1093/eurheartj/ehs232

Subject(s) - medicine , randomized controlled trial , acute coronary syndrome , cardiology , myocardial infarction

We sought to determine the degree of anticoagulation reversal required to mitigate bleeding, and assess the feasibility of using pegnivacogin to prevent ischaemic events in acute coronary syndrome (ACS) patients managed with an early invasive approach. REG1 consists of pegnivacogin, an RNA aptamer selective factor IXa inhibitor, and its complementary controlling agent, anivamersen. REG1 has not been studied in invasively managed patients with ACS nor has an optimal level of reversal allowing safe sheath removal been defined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research